Abstract

In England, only 30% of patients with established coronary heart disease (CHD) and raised serum lipids, and fewer than 4% of individuals eligible for primary prevention, receive lipid-lowering therapy.1 Target total cholesterol concentrations are achieved in fewer than 50% of patients who do receive such treatment.1 Here, we review the use of statin therapy in the prevention of CHD events.